AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AstraZeneca is currently conducting a Phase IIIb study titled ‘Capivasertib+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients.’ The study aims to evaluate the efficacy and safety of combining Capivasertib and Fulvestrant in treating hormone receptor-positive, HER2-negative breast cancer that has progressed after endocrine therapy. This research is significant as it targets a specific patient group in China, potentially offering new treatment avenues.
The study tests two drugs: Capivasertib, an oral medication taken twice daily for four days with a three-day break, and Fulvestrant, administered via intramuscular injections. These interventions aim to delay the time to the first subsequent treatment, providing a new therapeutic strategy for patients with advanced breast cancer.
The study is designed as an interventional, non-randomized, parallel assignment with no masking, focusing primarily on treatment. It involves two cohorts, with one receiving Capivasertib and Fulvestrant without prior Fulvestrant treatment, and the other involving patients who have previously been treated with Fulvestrant.
Key dates for this study include a start date of September 26, 2024, and the last update on June 24, 2025. These dates are crucial as they mark the study’s progression and the timeline for potential results that could influence treatment protocols.
The market implications of this study could be significant for AstraZeneca, potentially boosting stock performance and investor confidence if the results are positive. This study also positions AstraZeneca competitively within the oncology sector, particularly in the Chinese market, where there is a growing demand for advanced cancer treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.